الولايات المتحدة · وكالات وأخبار لحظية · PR Newswire

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

نشره PR Newswire · الولايات المتحدة منذ 1 س

DUBLIN, Oct. 21, 2026 /PRNewswire/ -- Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal photopheresis…

اقرأ المقال كاملًا على PR Newswire سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.prnewswire.com)

يستحق القراءة أيضًا

Associated Press (Business)

Here’s why Rubio is visiting a small Indian city home to world’s largest oil-refining complex

Business Wire

Accenture, Dragos and SANS Institute Launch Foundation to Strengthen Cyber Defenses for Under-Resourced U.S. Utilities

Dow Jones Newswires

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening

MT Newswires

Therakos Receives MDR Approval in Europe for Treating Immune-Related Adverse Events in Patients with Inadequate Response to Corticosteroids

مشاركة

يستحق القراءة أيضًا

Here’s why Rubio is visiting a small Indian city home to world’s largest oil-refining complex

Accenture, Dragos and SANS Institute Launch Foundation to Strengthen Cyber Defenses for Under-Resourced U.S. Utilities

Episode 49: Trump’s Tariffs Give Forced-Labor Activists an Opening

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows